295 related articles for article (PubMed ID: 33175853)
21. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
Ito M; Ehara Y; Li J; Inada K; Ohno K
Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
[TBL] [Abstract][Full Text] [Related]
22. Muscle specific kinase protects dystrophic mdx mouse muscles from eccentric contraction-induced loss of force-producing capacity.
Trajanovska S; Ban J; Huang J; Gregorevic P; Morsch M; Allen DG; Phillips WD
J Physiol; 2019 Sep; 597(18):4831-4850. PubMed ID: 31340406
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ
Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959
[TBL] [Abstract][Full Text] [Related]
24. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model.
Rodino-Klapac LR; Janssen PM; Shontz KM; Canan B; Montgomery CL; Griffin D; Heller K; Schmelzer L; Handy C; Clark KR; Sahenk Z; Mendell JR; Kaspar BK
Hum Mol Genet; 2013 Dec; 22(24):4929-37. PubMed ID: 23863459
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery.
Abmayr S; Gregorevic P; Allen JM; Chamberlain JS
Mol Ther; 2005 Sep; 12(3):441-50. PubMed ID: 16099410
[TBL] [Abstract][Full Text] [Related]
26. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
Gutpell KM; Hrinivich WT; Hoffman LM
PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
[TBL] [Abstract][Full Text] [Related]
27. Truncated dystrophins can influence neuromuscular synapse structure.
Banks GB; Chamberlain JS; Froehner SC
Mol Cell Neurosci; 2009 Apr; 40(4):433-41. PubMed ID: 19171194
[TBL] [Abstract][Full Text] [Related]
28. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.
Guiraud S; Edwards B; Babbs A; Squire SE; Berg A; Moir L; Wood MJ; Davies KE
Hum Mol Genet; 2019 Jul; 28(13):2189-2200. PubMed ID: 30990876
[TBL] [Abstract][Full Text] [Related]
29. C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice.
Yue Y; Liu M; Duan D
Mol Ther; 2006 Jul; 14(1):79-87. PubMed ID: 16563874
[TBL] [Abstract][Full Text] [Related]
30. Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models.
van der Pijl EM; van Putten M; Niks EH; Verschuuren JJ; Aartsma-Rus A; Plomp JJ
Eur J Neurosci; 2016 Jun; 43(12):1623-35. PubMed ID: 27037492
[TBL] [Abstract][Full Text] [Related]
31. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
Guiraud S; Edwards B; Squire SE; Moir L; Berg A; Babbs A; Ramadan N; Wood MJ; Davies KE
Hum Mol Genet; 2019 Jan; 28(2):307-319. PubMed ID: 30304405
[TBL] [Abstract][Full Text] [Related]
32. Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
Goyenvalle A; Babbs A; Wright J; Wilkins V; Powell D; Garcia L; Davies KE
Hum Mol Genet; 2012 Jun; 21(11):2559-71. PubMed ID: 22388933
[TBL] [Abstract][Full Text] [Related]
33. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.
Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G
Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126
[TBL] [Abstract][Full Text] [Related]
34. Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.
D'Arcy CE; Feeney SJ; McLean CA; Gehrig SM; Lynch GS; Smith JE; Cowling BS; Mitchell CA; McGrath MJ
Hum Mol Genet; 2014 Feb; 23(3):618-36. PubMed ID: 24087791
[TBL] [Abstract][Full Text] [Related]
35. Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function.
Chu X; Li J; Qiao C; Wang J; Wang Y; Jiang XC; You H; Xiao X; Wang B
FASEB J; 2021 Jun; 35(6):e21628. PubMed ID: 33982338
[TBL] [Abstract][Full Text] [Related]
36. Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy.
Péladeau C; Jasmin BJ
Methods Mol Biol; 2023; 2587():495-510. PubMed ID: 36401046
[TBL] [Abstract][Full Text] [Related]
37. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.
Burkin DJ; Wallace GQ; Nicol KJ; Kaufman DJ; Kaufman SJ
J Cell Biol; 2001 Mar; 152(6):1207-18. PubMed ID: 11257121
[TBL] [Abstract][Full Text] [Related]
38. Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice.
Xin C; Chu X; Wei W; Kuang B; Wang Y; Tang Y; Chen J; You H; Li C; Wang B
Hum Mol Genet; 2021 Jun; 30(14):1349-1359. PubMed ID: 33987645
[TBL] [Abstract][Full Text] [Related]
39. [Gene therapy for muscular dystrophy].
Takeda S
No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
[TBL] [Abstract][Full Text] [Related]
40. Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient Mice.
Heller KN; Montgomery CL; Shontz KM; Clark KR; Mendell JR; Rodino-Klapac LR
Hum Gene Ther; 2015 Oct; 26(10):647-56. PubMed ID: 26076707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
